April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Visual outcome in 26 blind retinitis pigmentosa patients after implantation of subretinal Alpha-IMS devices
Author Affiliations & Notes
  • Eberhart Zrenner
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Karl-Ulrich Bartz-Schmidt
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Caroline Chee
    Dept.of Ophthalmology, National University Health System, Singapore, Singapore
  • Florian Gekeler
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Timothy L Jackson
    Dept. of Ophthalmology, School of Medicine,, King's College, London, United Kingdom
  • Robert MacLaren
    Dept. of Clinical Neurosciences, Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, United Kingdom
  • Janos Nemeth
    Semmelweis University, Budapest, Hungary
  • Helmut Sachs
    Städtisches Klinikum Dresden-Friedrichstadt, Dresden, Germany
  • Katarina Stingl
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • David Wong
    Dept. of Ophthalmology, University of Hong Kong, Hong Kong, Hong Kong
  • Footnotes
    Commercial Relationships Eberhart Zrenner, Retina Implant AG (F), Retina Implant AG (I), Retina Implant AG (P), Retina Implant AG (R), Retina Implant AG (S); Karl-Ulrich Bartz-Schmidt, Retina Implant AG (F); Caroline Chee, None; Florian Gekeler, Retina Implant AG (C), Retina Implant AG (F), Retina Implant AG (P); Timothy Jackson, Retina Implant AG (F); Robert MacLaren, Retina Implant AG (C), Retina Implant AG (F); Janos Nemeth, Retina Implant AG (F); Helmut Sachs, Retina Implant AG (F); Katarina Stingl, Retina Implant AG (F), Retina Implant AG (R); David Wong, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5967. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eberhart Zrenner, Karl-Ulrich Bartz-Schmidt, Caroline Chee, Florian Gekeler, Timothy L Jackson, Robert MacLaren, Janos Nemeth, Helmut Sachs, Katarina Stingl, David Wong, ; Visual outcome in 26 blind retinitis pigmentosa patients after implantation of subretinal Alpha-IMS devices. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5967.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To assess the 12-month visual and safety outcomes following implantation of a 1500-pixel subretinal implant in patients blind from retinitis pigmentosa (RP).

Methods: Alpha-IMS subretinal implants (Retina Implant AG, Reutlingen, Germany) were positioned beneath the foveal region of 14 male and 12 female RP-patients (mean age 53.2 ± 8.2). Each of the 1500 subfoveal photodiodes within a 11° by 11° field controls an amplifier that, depending on the strength of the light, emits currents to stimulate overlying bipolar cells. Power and control signals are supplied inductively via a subdermal, retroauricular coil from which a subdermal cable leads to the eyeball. Function was tested by 4 procedures - 1: Monitor-based standardized tests for light perception, light localization, movement detection, grating acuity and visual acuity with Landolt C-rings (2- or 4 alternative-force-choice-tests); 2: Detection, localization and identification of objects placed on a table; 3: Reading letters; 4: Visual experiences during outdoor and daily-life activities.

Results: 1: Implant-mediated light perception was possible for 22 (85%) patients; light localization for 15 (58%); movement detection (up to 35 cycles/degree) for 6 (23%); measurable grating acuity (up to 3.3 cycles/degree) for 14 (54%); and measurable visual acuity (up to 20/546) for 4 (18%). 2: On a visual ability scale from 0 (worst) to 4 (best) for 4 white geometric figures presented on a black table, patients averaged 3.12 ± 0.31 for detection, 2.94 ± 0.3 for localization and 1.06 ± 0.28 for identification at month 2 which was significantly better (p< 0.012) than with chip power switched off. Similar results were obtained with activities of daily living. Losses of approximately 1-1.5 units occured over 9-12 months. 3: Four patients (18%) could read letters 4-8 cm in size. 4: Twelve patients (46%) reported useful visual experiences including recognition of details and 7 patients (27%) could localize objects in daily life without details. 5: Besides two treatable serious adverse events there were no safety concerns.

Conclusions: The Alpha-MS implant has a CE mark for commercial use in Europe. Psychophysical testing and self-reported outcomes show restoration of useful vision in a majority of patients. Subretinal implantation surgery is safe and a multicenter study is continuing with a slightly modified implant to establish long term durability.

Keywords: 696 retinal degenerations: hereditary • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×